Trial Profile
National Cerebral and Cardiovascular Center (NCVC) Stroke Registry
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Stroke; Transient ischaemic attacks
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2023 Planned End Date changed from 1 Mar 2025 to 1 Mar 2028.
- 07 Nov 2023 Planned primary completion date changed from 1 Jun 2021 to 1 Mar 2027.
- 21 Apr 2020 Planned End Date changed from 1 Mar 2017 to 1 Mar 2025.